In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR/Cas9 patent portfolio.

Dr Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio stands as the definitive collection of proprietary rights to this gene editing technology.

Founded in 2012, Transomic’s mission is to equip life science researchers with cutting-edge gene modulation tools derived from the forefront of biotechnology advancements. Specializing in molecular cloning, their portfolio of products and services revolves around vector-based solutions.

Commenting on the agreement with ERS, Blake Simmons, CEO, Transomic Technologies, said: “Transomic recognizes the extremely valuable role that gene-editing technology plays in life science research and drug discovery.
“We are very excited to be able to continue to expand our CRISPR/Cas9 research tool business by licensing this important patent portfolio from ERS genomics.”

Blake Simmons, CEO,
Transomic Technologies